Cytek Biosciences Posts $0.01 Q4 Loss, Beats Revenue by 0.23%
Cytek Biosciences reported a Q4 adjusted loss of $0.01 per share versus a $0.02 per share estimate, after earning $0.07 per share a year earlier. Revenue rose 8.1% year-over-year to $62.14 million, topping estimates by 0.23%, while shares have fallen 13.5% year-to-date and next quarter EPS is forecast at -$0.04.
1. Q4 Earnings Results
Cytek Biosciences posted an adjusted net loss of $0.01 per share in the quarter ended December 2025, missing market expectations of a $0.02 per share profit and reversing from last year’s $0.07 per share gain. This marked the second consecutive negative surprise on the bottom line.
2. Revenue Breakdown
Quarterly revenue rose 8.1% year-over-year to $62.14 million, surpassing consensus forecasts by 0.23%. This marks two revenue beats in the past four quarters, driven by strength in its biomedical and genetics product lines.
3. Stock Performance and Outlook
Shares have slid 13.5% since January, underperforming the broader market’s 1.5% gain over the same period. Analysts project a -$0.04 EPS for next quarter on $44.44 million in revenue, placing near-term performance hinge on upcoming guidance.